Helen McShane

From WikiProjectMed
Jump to navigation Jump to search

Helen McShane
FRCP
Helen McShane in the video Exposed
Born
Helen Irene McShane
Alma materUniversity of London (PhD)
Scientific career
FieldsTuberculosis vaccines
Immunology
HIV[1]
InstitutionsUniversity of Oxford
Jenner Institute
ThesisImmunisation strategies for enhancing T cell responses against M. tuberculosis (2002)
Websitewww.ndm.ox.ac.uk/principal-investigators/researcher/helen-mcshane Edit this at Wikidata

Helen Irene McShane FRCP is a British infectious disease physician and a professor of vaccinology, in the Jenner Institute at the University of Oxford, where she has led the tuberculosis vaccine research group since 2001.[1][2] She is senior research fellow at Harris Manchester College, Oxford.[3]

Education

Helen McShane first studied at the University of London, where she obtained an intercalated Bachelor of Science degree in psychology in 1988 followed by a Bachelor of Medicine, Bachelor of Surgery (MB BS) in 1991. She was subsequently awarded a Doctor of Philosophy from the University of London in 2002 for research investigating immunisation strategies for enhancing T cell responses against Mycobacterium tuberculosis.[4]

Career and research

After receiving her degree in medicine from the University of London, her first hospital jobs were in Brighton. Whilst working with patients with HIV she became interested in infectious diseases, before moving to Oxford where she was appointed a specialist registrar for infectious diseases. After her PhD in 2002[4] she received a Wellcome Trust science research fellowship and starting her own tuberculosis vaccine research group there.[5] She was appointed a clinical consultant in 2003.[6] She is an honorary consultant in HIV and genito-urinary medicine at the Oxford University Hospitals.[7]

Since 2002, the Tuberculosis Vaccine Initiative Advisory Committee (TBVI), of which McShane is the chair, has conducted clinical trials of candidate vaccines developed at the Jenner Institute, including MVA85A[8] and ChAdOx1 85A in the United Kingdom, The Gambia, South Africa, Senegal and Uganda.[9][10][11] MVA85A is the first TB vaccine candidate in this cohort to be tested for efficacy in humans.[5]

The committee is also currently investigating whether delivering a TB vaccine via the aerosol route (nebulisation directly into the lungs) is a more effective method of vaccination. McShane has authored or co-authored over 100 peer-reviewed publications.[1][2][5]

Awards and honours

In 2019, McShane was named amongst other colleagues as a National Institute for Health Research (NIHR) Senior Investigator, in recognition of her "outstanding contribution to clinical and applied health and social care research".[12] McShane is also a Fellow of the Royal College of Physicians (FRCP).

References

  1. ^ a b c Helen McShane publications indexed by Google Scholar Edit this at Wikidata
  2. ^ a b Helen McShane publications from Europe PubMed Central
  3. ^ "Academics - Professor Helen McShane". hmc.ox.ac.uk. 2020. Retrieved 13 October 2020.
  4. ^ a b Mcshane, Helen Irene (2002). Immunisation strategies for enhancing T cell responses against M. tuberculosis. london.ac.uk (PhD thesis). University of London. OCLC 1000835837. EThOS uk.bl.ethos.271722.
  5. ^ a b c "Helen McShane, Professor of Vaccinology, Wellcome Senior Clinical Fellow at The Jenner Institute Laboratories - Relationship Science". relationshipscience.com. Retrieved 29 June 2019.
  6. ^ "Helen McShane — Diversity Projects". diversityprojects.ox.ac.uk. Retrieved 29 June 2019.
  7. ^ Ord, Chris (27 September 2018). "Multi-tasker Prof Helen McShane is waging war on diseases". oxfordtimes.co.uk. The Oxford Times. Retrieved 1 July 2019.
  8. ^ Tameris, Michele D; Hatherill, Mark; Landry, Bernard S; Scriba, Thomas J; Snowden, Margaret Ann; Lockhart, Stephen; Shea, Jacqueline E; McClain, J Bruce; Hussey, Gregory D; Hanekom, Willem A; Mahomed, Hassan; McShane, Helen (2013). "Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial". The Lancet. 381 (9871): 1021–1028. doi:10.1016/S0140-6736(13)60177-4. ISSN 0140-6736. PMC 5424647. PMID 23391465.
  9. ^ McShane, Helen; Pathan, Ansar A; Sander, Clare R; Keating, Sheila M; Gilbert, Sarah C; Huygen, Kris; Fletcher, Helen A; Hill, Adrian V S (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans". Nature Medicine. 10 (11): 1240–1244. doi:10.1038/nm1128. ISSN 1078-8956. PMID 15502839. S2CID 13791082.
  10. ^ "Professor Helen McShane FMedSci FRCP - Nuffield Department of Medicine". ndm.ox.ac.uk. Retrieved 29 June 2019.
  11. ^ Finnegan, Gary (22 March 2019). "A new TB vaccine is within reach – Prof. Helen McShane". horizon-magazine.eu. Horizon: the EU Research & Innovation magazine. Retrieved 1 July 2019.
  12. ^ "Oxford medical researchers win prestigious national awards | NIHR Oxford Biomedical Research Centre". oxfordbrc.nihr.ac.uk. 14 March 2019. Retrieved 29 June 2019.
Retrieved from "https://mdwiki.org/wiki/Helen_McShane"